Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
IMVT-1402 (Immunovant/Roivant Sciences), Descartes-08 (Cartesian Therapeutics), Remibrutinib (Novartis), FABHALTA (Iptacopan) (Novartis), Gefurulimab (Alexion AstraZeneca Rare Disease), MAVENCLAD (Cladribine) (Merck KGaA), Telitacicept (RemeGen), Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), along with other emerging therapies advancing through clinical development. New York, USA, April 15, 2026 (GLOBE NEWSWIRE) Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight The generalized myasthenia gravis treatment pipeline features several promising late-stage candidates, including IMVT-1402 (Immunovant/Roivant Sciences), Descartes-08 (Cartesian Therapeutics), Remibrutinib (Novartis), FABHALTA (Iptacopan) (Novartis), Gefurulimab (Alexion AstraZeneca Rare Disease), MAVENCLAD (Cladribine) (Merck KGaA), Telitacicept (RemeGen), Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), along with other emerging the
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant (IMVT) had its "neutral" rating reaffirmed by The Goldman Sachs Group, Inc..MarketBeat
- Immunovant (IMVT) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM [Yahoo! Finance]Yahoo! Finance
- Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP [Yahoo! Finance]Yahoo! Finance
- Immunovant shares plunge after phase 3 trials fails to meet primary endpoint [Yahoo! Finance]Yahoo! Finance
IMVT
Earnings
- 2/6/26 - Beat
IMVT
Sec Filings
- 4/10/26 - Form 4
- 4/10/26 - Form 4
- 4/10/26 - Form 4
- IMVT's page on the SEC website